CILTACABTAGENE AUTOLEUCEL

USDailyMed:Ciltacabtagene autoleucel AU:C L01XL05(WHO) AU:C4 (class 4 biological)CA:℞-only/Schedule DUS:℞-onlyEU:Rx-only DB16738 0L1F17908Q D12315 Ciltacabtagene autoleucel, sold under the brand nameCarvykti, is ananti-cancer medicationused to treatmultiple myeloma.Ciltacabtagene autoleucel is a BCMA (B-cell maturation antigen)-directed genetically modified autologouschimeric antigen receptor (CAR) T-celltherapy.Each dose is customized using the recipient's own T-cells, which are collected, genetically modified, and infused back into the recipient. The most common adverse reactions‍‍‍‍‍‍​​​‍​​​​​​ include pyrexia, hypogammaglobulinemia, musculoskeletal pain, fatigue, infections, diarrhea, nausea, encephalopathy, headache, coagulopathy, constipation, and vomiting.Additional common side effects include neutropenia (low levels of neutrophils), lymphopenia and leucopenia (low levels of lymphocytes or other white blood cells), anemia (low levels of red blood cells), thrombocytopenia (low levels of blood platelets), hypotension (low blood pressure), pain of the muscles and bones, high level of liver enzymes, upper respiratory tract infection (nose and throat infection), diarrhea, hypokalemia (low level of potassium), hypocalcemia (low levels of calcium), hypophosphatemia (low levels of phosphate in the blood), nausea, headache, cough, tachycardia (rapid heartbeat), encephalopathy (a brain disorder), edema (fluid retention), decreased appetite, chills, fever, tiredness, as well as cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure). Ciltacabtagene autoleucel was approved for medical use in the United States in February 2022,and in the European Union in May 2022.